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Recently, conflicting results have been reported on the incidence of RAS mutations in primary testicular germ cell tumors of 
adults (TGCTs). In four studies a low incidence of mutations (less than 15%) in a variety of TGCTs or derived cell lines was 
found, whereas in two other studies a high incidence of N- or KRAS mutations (over 40%) was shown. A total of 62 testicular 
seminomas (SE) and 34 nonseminomatous TGCTs (NS) were studied thus far. The largest series consisted of 42 TGCTs, studied 
on paraffin embedded tissue. We present the results of analysis for the presence of N- and KRAS mutations, in codons 12, 13, 
and 6 I, in snap frozen samples of I00 primary TGCTs, comprising 40 SE and 60 NS. Using the polymerase chain reaction (PCR) 
and allele specific oligonucleotide hybridization (ASO), mutations were found in five SE (three in NRAS and two in KRAS, all 
codon I2), and in one NS (KRAS, codon 12). To exclude underestimation of the incidence of RAS mutations in TGCTs due to  
the presence of an excess of wild type alleles in the analyzed sample, a PCR technique preferentially amplifying KRAS alleles with 
a mutation in codon I 2  was applied to  all SE. This approach, allowing a 250 times more sensitive assay, resulted in the detection 
of only one additional SE with a mutation. Based on a critical analysis of published data and on our results from the largest series 
of frozen samples investigated thus far, we conclude that N- or KRAS mutations are rare and apparently not essential for 
initiation or progression of TGCTs. Genes Chromosom Cancer I2 : I  10-1 16 (1995). 0 1995 Wiley-Liss, Inc. 
INTRODUCTION 
T h e  p21 proteins encoded by N-, H- and KRAS 
are involved in signal transduction from activated 
receptors in the cellular membrane to the nucleus. 
h4utations in these genes, particularly those in 
codons 12, 13, and 61, cause a decrease in intrinsic 
GTPase activity, leading to constitutive activation 
of the encoded protein (Rodenhuis, 1992; McCor- 
mick, 1993). RAS mutations have been detected in 
a wide variety of human neoplasms, although with 
varying incidence (Rodenhuis, 1992), and are con- 
sidered to represent only one of many events in the 
multistep process of transformation (Kumar et al., 
1990). 
A low incidence of KRAS codon 12 mutations 
(less than 15%) has been found in all studies on 
human primary testicular germ cell tumors 
(TGCTs)  (Mulder et al., 1989; Ganguly et al., 
1990; Moul et al., 1992; Ridanpaa et al., 1993). In 
contrast, conflicting data have been reported for 
NRAS. One study showed mutations at codon 12 or 
61 in 13 of 20 seminomas (SE) and two of three 
nonseminomatous T G C T s  (NS) (Ganguly et al., 
1990). Another study, comprising only SE, re- 
vealed NRAS codon 61 mutations in four of 14 tu- 
mors (Mulder et al., 1989). No mutations were 
found in NRAS codons 12 or 61 in two studies, 
comprising 28 SE and 31 NS ( M o d  et al., 1992; 
Ridanpaa et al., 1993). A consistent finding is the 
absence of mutations in NRAS codon 13; HRAS 
codon 12, 13, and 61; and KRAS codons 13 and 61 
in T G C T s  and derived cell lines (Mulder et al., 
1989; Dniitrovsky et al., 1990; Ganguly et al., 
1990; Tesch et al., 1990; Moul et al., 1992; Ri- 
danpaa et al., 1993). 
Several factors may explain the varying findings 
on the incidence of RAS mutations in TGCTs.  Be- 
sides possible geographical influences (Rodenhuis, 
1992), technical factors related to the method of 
fixation of the tissue samples, frozen (Mulder et al., 
1989; Ganguly et al., 1990; Ridanpaa et al., 1993) 
versus paraffin embedded (Moul et al., 1992), 
might be involved. In addition, the applied poly- 
merase chain reaction and allele specific oligonu- 
cleotide hybridization (PCWASO) might underes- 
timate the incidence of mutations when an excess 
of wild type alleles is present, since it allows de- 
tection of one mutant among 40 wild type alleles 
(Slebos et a]., 1992). This could especially be im- 
portant for SE, which may contain a high percent- 
age (over 80%) of nonmalignant cells (Mostofi et al., 
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1987; hlulder et al., 1989). To  overcome this prob- 
lem, Mulder et al. (1989) used suspensions of SE 
nuclei sorted on the basis of their aneuploid DNA 
content. An alternative is the use of a PCR tech- 
nique which pre:ferentially amplifies mutant alleles 
(mutant-enriched PCR, MEPCR). It has been 
shown by Kahn et al. (1991) that this approach 
allows detection of one mutant among 10,000 wild 
type alleles using A S 0  (MEPCWASO). 
We have studied snap frozen samples of 100 pri- 
mary TGCTs,  comprising 40 SE and 60 NS, using 
PCWASO for detection of N- and KRAS codons 12, 
13, and 61 mutations. I n  addition, MEPCWASO 
for KRAS codon 12 was used on all SE. 
MATERIALS AND METHODS 
Tumor Samples 
One hundred primary T G C T s  and adjacent pa- 
renchyma (when present) were collected at the op- 
eration theatres of collaborating hospitals. After fro- 
zen section diagnosis (using a haematoxylin and 
eosin stained tis:jue section), representative parts of 
tumor and adjacent parenchyma were snap frozen in 
liquid NZ. Typing according to the WHO classifi- 
cation (Mostofi t:t a]., 1987) was based on histology 
and imniunohistochemical analyses of expression of 
placental-like alkaline phosphatase (PLAP), alpha 
fetoprotein (AFF'), human chorionic gonadotropin 
(hCG) (Dako, Glostrup, DK), and cytokeratins 8 
and 18 (Beckton Dickinson, San Jose, CA) using 
representative p:araffin and frozen tissue sections, as 
described (Oosterhuis et al., 1989). 
Frozen samples destined for DNA extraction 
were microscopically checked for the presence of 
tumor cells. In addition, suspensions of cell nuclei 
were prepared from 25 N S  samples. These were 
stained with propidium iodide and analysed by 
flow cytometry to determine the fractions of aneu- 
ploid and diploid cells as described by Mulder et 
al. (1989). 
DNA Extraction 
DNA was extracted from snap frozen tumor sam- 
ples, as described (Maniatis et al., 1982). From 
each sample three 10 p m  thick sections were col- 
lected in 100 p1 lysis buffer (10 mM Tris, 400 mM 
NaCI, 2 mM EDTA, 1% SDS, 10 pg/ml proteinase 
K (Sigma, St. Louis, MO), pH 8.2) and lysed over- 
night at 37°C. Subsequently the samples were ex- 
tracted twice with an equal volume of phenol/chlo- 
roform. After precipitation in ethanol/sodium 
acetic acid, the DNA pellet was dissolved in 10 
mM Tris, 0.1 mM EDTA to a final concentration 
of approximately 0.5 pg/pI. From each sample 0.5 
pl (approx. 250 ng DNA) was used for PCR. T h e  
agarose gel electrophoresis performed to confirm 
the presence of PCR products, as described in the 
next section, was also used to confirm the presence 
of comparable amounts of DNA in each PCR. 
Matched, carcinoma-in situ containing parenchyma 
of tumors with a RAS mutation was also studied, 
when available (n = 4). 
Polymerase Chain Reaction 
Amplification was performed in a reaction mix- 
ture which consisted of buffer (50 niM KCI, 2.5 
mM MgCI,, 10 mM Tris-HCI (pH 8.0), 10 mM 
NaCI, 0.01 mM EDTA, 0.5 mM D T T ,  0.1% Tri- 
ton X-100) (Promega, Madison, WI), 0.2 mM of 
each nucleotide (dATP, d T T P ,  dCTP,  dGTP) 
(Pharmacia, Woerden, the Netherlands), 1 U Taq 
polymerase (Promega), 0.5 pM of both sense and 
anti-sense primer in a total volume of 50 pl. Four 
different primer sets, described by Verlaan-de 
Vries et al. (1986), were used to amplify the KRAS 
12 and 13, KRAS 61, NRAS 12 and 13, and NRAS 
61 regions. T h e  reaction mixture was covered with 
paraffin oil. Samples were placed in a Thermal Cy- 
cler (Perkin-Elmer, Nonvalk, VA) and heated to 
94°C for 1 min. T h e  PCR included 35 cycles of 
denaturation at 94°C for 30 sec, annealing at 54°C 
for 30 sec, and extension at 72°C for 1 min. Finally, 
the samples were kept at 72°C for 2 min and sub- 
sequently stored at 4°C till further analysis. All 
samples were tested for the presence (or absence, 
in the negative control, containing H,O instead of 
DNA) of the desired fragment by agarose gel elec- 
trophoresis and ethidiuni-bromide staining, using 3 
11.1 of the PCR mixture. 
Mutant-Enriched Polymerase Chain Reaction 
for KRAS Codon I 2  
Amplification was performed in a reaction mix- 
ture which consisted of buffer (3.5 mM MgCI,, 15 
mM (NH,),SO,, 60 mM Tris-HCI pH 8.4), 0.2 
mM of each nucleotide (dATP, d T T P ,  dCTP,  
dGTP), 1.5 U Taq  polymerase, 1 p M  of both 
sense and anti-sense primer in a final volume of 50 
pl. Using a mismatched sense primer (introducing 
a BstNl restriction site in the wild type allele) to- 
gether with an antisense primer (Kahn et al., 
1991), KRAS 12 regions were amplified. T h e  sam- 
ples were heated to 96°C for 5 min, followed by 
one cycle at 96°C for 2 min, 55°C for 1 min, and 
73°C for 1 min. During 24 cycles, the samples were 
brought to 96°C for 30 sec, 55°C for 30 sec, and to 
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73°C for 1 min. Each sample (12.5 11.1) was then 
digested overnight a t  370°C to completion with 5 U 
endonuclease M v n l ,  an isoschizomer for BstNl 
(Boehringer, Mannheim, Germany), in 26 p1 
buffer H (50 mM Tris-HCI, p H  7.5, 10 mM 
MgCI,, lOOmMNaCI, 1 mMdithioerythritol)(Boeh- 
ringer, Mannheim, Germany). In a second round 
of PCR, under the same conditions as described 
above, except for the use of the mismatched sense 
primer and a nested antisense primer, only the un- 
cleaved (mutated) fragments were amplified. T o  
show the effect of mutant-enrichment the second 
PCR was also applied to undigested amplification 
product of the first PCR. 
Allele Specific Oligonucleotide Hybridization 
Paraffin oil was removed from the PCR-samples 
by extraction with diethyl ether. DNA was dena- 
tured at 96°C for 3 rnin and 1 pl of PCR mixture 
from each sample was dotted on a dry Nytran-N 
membrane (Schleicher & Schuell, Dassel, Ger- 
many), which had previously been soaked in HZO 
and 10 x SSC, and air dried. DNA from previously 
characterized mutation-carrying samples was used 
as positive control. These controls were available 
for all KRAS 12 positions (Slebos et al., 1990) and 
for KRAS 13 position 1 and KRAS 61 position 3 
(Oudejans et al., 1991). As negative control a sam- 
ple of the PCR mixture without DNA was used. 
DNA was crosslinked to the membrane by expo- 
sure to UV light for 2 min. 
T h e  N- and KRAS 12 and 13 wild type alleles 
were detected by specific wild type probes, and 
identification of KRAS 12 mutations was performed 
using 6 specific probes after conventional PCR, 
and 6 after mutant-enriched PCR (Verlaan-De 
Vries et al., 1986; Kahn et al., 1991). Two mixtures 
of three probes (codon positions 1 and 2) were used 
for KRAS 13 and i'VRAS 12 and 13, while for KRAS 
61 and NRAS 61 three mixtures of three mutation 
specific probes (for positions 1, 2, or 3 of the 
codons) were applied (Verlaan-De Vries et al., 
1986). Five picomoles (1 pl) of probe was endla- 
beled using 2.5 LJ T 4  polynucleotide kinase (PNK) 
(Gibco BRL, Breda, the Netherlands) in 4 pI re- 
action mix (50 mM Tris.HCI pH 7.6, 10 mM 
MgCl,, 5 mM D T T ,  0.1 mM EDTA, 0.1 mM 
spermidine, 10 pCi (1 pl) "P y-ATP (Amersham, 
Den Bosch, the Netherlands). After incubation at 
37°C for 30 min, 70 pl of 10 mM Trid0.1 mM 
EDTA and 1 pI tRNA were added and the mix was 
centrifuged through a Clontech-100 column (Clon- 
tech Laboratories, Palo Alto, CA). 
All blots were soaked in aqua dest in separate 
hybridization tubes. T h e  aqua dest was replaced 
by 2 ml hybridisation mix (3 M tetramethylammo- 
nium chloride, 50 mM Tris pH 7.5, 5 mhl EDTA, 
1% SDS, 1% (w/v) milk protein (Protifar) (Nutri- 
cia, Zoetermeer, the Netherlands). After prehy- 
bridization for 60 rnin at 56"C, 20 pI of labeled 
probe was added and hybridization was done for 1 
hr at 56°C. Blots were washed in hybridization mix 
without milk protein at 56°C for 30 min, taken 
from the tubes, rinsed with 2 x SSC (0.3 M NaCI, 
0.03 M sodium citrate, pH 7.0), dried, and ex- 
posed overnight to an XomatAR film (Eastman 
Kodak, Rochester, NY) at -70°C. Subsequently, 
blots were washed at higher stringency in 5 x 
SSPE (50 mM sodium phosphate, 0.9 M NaCI, 
5mM EDTA)/O.l% SDS, for 30 min, to remove 
any probe mismatched to the PCR product. In the 
PCWASO, temperature was kept at 57°C for NRAS 
61, 59°C for KRAS 61, 61°C for NRAS 12 and 13, 
and 63°C for KRAS 12 and 13, while the tempera- 
ture was 61°C in the MEPCWASO for KRAS 12. 
T h e  blots were again rinsed with 2 x SSC, dried, 
and exposed for 1 to 4 days, as described. Muta- 
tions could be detected comparing the dot signals 
obtained before (to verify the presence of PCR 
products) and after the stringent wash. 
Identification of Mutations 
T h e  exact nature of the NRAS 12 mutations was 
revealed by a cycle sequencing protocol (Cycle Se- 
quencing Kit, Perkin-Elmer Cetus, Nonvalk, C T )  
using a "P-labeled sense primer. In brief, the tu- 
mor samples were amplified in triplicate using con- 
ventional PCR. T h e  PCR products were pooled 
and subjected to electrophoresis on a 2.5% prepar- 
ative agarose gel. T h e  fragments were excised from 
the gel and incubated with 6 U agarase (Boeh- 
ringer, Mannheim, Germany) for 1 hr at 45°C. T h e  
purified DNA fragments were ethanol precipitated 
at -70°C for 15 rnin and dissolved in 25 p,l of 
sterile water. Twenty cycles of denaturation at 
95°C (1 rnin), annealing at 63°C (1 .5  min), and 
extension at 72°C (2 min) were performed in a ther- 
mal cycler (Hybaid'", Teddington, United King- 
dom). The sequencing reactions were analyzed on 
a denaturing 6% polyacrylaniide sequencing gel at 
60 W for 2.5 hr. T h e  gel was exposed at -70°C for 
16 hr as described above, with an intensifying 
screen. 
RESULTS 
Classification of the obtained tumors revealed 40 
SE and 60 NS. T h e  group of N S  comprised 22 pure 
tumors (12 embryonal carcinomas [ EC], four yolk 
sac tumors [YS], five teratomas [TI  [both mature 
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Figure I .  D o t  blot signals (after high stringency wash) of all mutant 
tumors after amplification of the N- or KRAS I 2  region, using PCWASO 
or MEPCWASO. TL = tumor; P = parenchyma adjacent to the tumor; 
D O T  signal of the mutant tumor; -T = signal of a representative 
mutation-negative tumor; + C = signal of the corresponding positive 
and immature] and one choriocarcinoma [CHI), 35 
tumors containing E C  mixed with one or more other 
components (CH[, SE ,  T, YS), two tumors contain- 
ing CH and T, and one tumor containing T and YS. 
A low incidence of codon 12 mutations was 
found in both N- and KRAS, whereas no mutations 
in  N- or KRAS 13 or 61 were detected in any of the 
analyzed TGCTs. Three  SE (TL1049, TL2191, 
and TL3544) were found with a mutation in NRAS 
12, while two SE (TL7573, TL8837) and one NS 
(TL2308, containing EC,  T ,  and YS) with a KRAS 
12 mutation were detected (Fig. 1). 
Using the PCWASO approach, mutations in 
some tumor samples might have remained unde- 
tected due  to the presence of an excess of wild type 
alleles. Therefore suspensions of cell nuclei were 
prepared from 25 frozen NS samples, stained with 
propidium iodide, and analysed by flow cytometry 
to determine the fraction of aneuploid (tumor) and 
diploid (nontumor) cells. T h e  fraction of aneuploid 
cells varied between 22 and 93%, while 18 tumors 
contained more than 50% aneuploid cells. 
It has previously been shown that in S E  samples 
the fraction of nontumor cells can be greater than 
90% (Mulder et  al . ,  1989). We therefore decided to 
repeat the mutation analysis in our series of S E  
using MEPCR/ASO for KRAS 12. In  this procedure 
mutant alleles are preferentially amplified, hereby 
allowing the detection of one mutant among 10,000 
wild type alleles (Kahn et al., 1991). T h e  analysis 
revealed one extra mutant SE (TL614).  T h e  pre- 
viously detected mutations were confirmed, show- 
ing an intensified signal after MEPCR/ASO, com- 
control containing a G G T  to GCT transition (for TL6 14). a GGT to T G T  
transition (for TL2308), or a GGT to  C G T  transition (for TL7573 and 
TL8837); - and + indicate MEPCWASO without, respectively, with 
Mval digestion of the product from the first PCR, resulting in mutant 
enrichment for the + condition. 
pared to PCWASO and MEPCWASO without 
Mval digestion (Figs. 1 and 2). 
Parenchyma adjacent to a mutant tumor was 
available for TL614, TL2308, TL3544, TL7573, 
and TL8837. Only the parenchyma of TL614 did 
not contain carcinoma in situ (CIS), the precursor of 
all T G C T s  (Skakkebzk et al., 1987) and therefore 
this sample was not studied further. In the paren- 
chyma of TL7573 and TL8837 a weak signal was 
found using MEPCWASO withoutMva1 digestion, 
while no signal was found for TL2308 (Fig. 1 and 
2). Using MEPCWASO the signals for the paren- 
chyma of TL7573 and TL8837 were intensified, 
while the mutation in TL2308 was now detectable. 
Since the parenchyma of TL7573 and TL8837 con- 
tained micro-invasive SE cells we cannot determine 
whether the RAS mutation was only present in these 
S E  cells or also in the CIS component. However, 
the findings for the parenchyma of TLZ308, con- 
taining only CIS, indicate that RAS mutations can 
occur in a noninvasive precursor lesion. No NRAS 
mutation was found in the parenchyma of TL3544 
(not shown). Since only PCR/ASO was used to de- 
tect NRAS mutations, the presence of a mutation in 
the  CIS cells cannot be excluded, in analogy to the 
findings for the parenchyma of TL2308. 
T h e  nature of the detected mutations is summa- 
rized in Table 1, showing identical base conversions 
in both the tumor and the adjacent parenchyma. 
DISCUSSION 
Since no HRAS mutations have been detected 
in  T G C T s  or derived cell lines (Mulder et al., 
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Figure 2. Example of dot blot analyses of mutant-enriched poly- 
merase chain reaction products for detection of KRAS I 2  mutants. The 
upper A-D panel represents results using the wild-type specific probe, 
which detects GGT. The lower A-D panel represents results after 
hybridization with the probe specific for the CGT sequence. Both blots 
were exposed after washing at high stringency. The first six positions 
(AI-A6) represent the positive controls for all possible mutations of 
the first or second base of codon I 2  (A3 corresponding with CGT). The 
remaining positions (A7, D8) are examples of testicular germ cell tu- 
mors, with paired signals from each tumor: without (left dot) and with 
Mvol digestion (right dot) after the first amplification. For example: C7 
(without digestion) and CB (with digestion) = parenchyma of tumor 
TL7573, note the enhancement in signal intensity after Mval digestion 
using the mutant specific probe; 85  and 86 = tumor HT85; D I and D2 
= tumor TL7573; D3 and D4 = parenchyma of tumor TL8837; D5 and 
D6 = tumor TL8837. 
1989; Dmitrovsky et al., 1990; Ganguly et al., 
1990; Tesch et al., 1990; Moul et al., 1992; Ri- 
danpai et al., 1993), we did not screen our samples 
for mutations in this gene. To  analyse the inci- 
dence of N- and KRAS codon 12, 13, and 61 mu- 
tations, the PCWASO was applied to 100 primary 
TGCTs ,  while all 40 SE in this series were also 
subjected to MEPCR/ASO to detect mutations in 
KRAS codon 12. Only six SE and one NS were 
found to contain a RAS mutation. Six of these mu- 
tations (five in SE and one in NS) were already 
detected using PCWASO. Our data, showing an 
incidence of KRAS mutations of 4%, are concor- 
dant with those reported (Mulder et al., 1989; Gan- 
guly et al., 1990; Moul et al., 1992; Ridanpis et 
al., 1993). Although using the same approach (fro- 
zen samples and conventional PCWASO), we did 
not find a high percentage of mutations in NRAS 12 
and 61, as reported by Ganguly et al. (1990). This 
could be due to difficulties in their interpretation 
of the mutation-specific hybridization signals. 
TABLE I. Summary of the Nature of the N- and KRAS 
Codon I2  Mutations in Testicular Seminomas (SE) and 
Testicular Nonserninomatous Germ Cell Tumors (NS). and 
Their Adiacent Carcinoma In Situ Containing Parenchyma (P) 
NRAS 12 KRAS 12 







































g l v a r g  
g l r a r g  
Taking into account the sensitivities of the two 
detection methods used (one mutant among 40 or 
one mutant among 10,000 wild type alleles for 
PCWASO and MEPCWASO, respectively), the 
minimal percentage of mutant alleles that needs to 
be present for detection can be calculated. A con- 
sistent overrepresentation of (parts of) 12p, on 
which KRAS is located, is found in T G C T s  (De 
Jong et al.,  1990; Oosterhuis et al., 1990; Ro- 
driquez et al., 1993a,b), with a mean copy number 
of about six. Assuming the presence of one mutant 
(codon 12) and five wild type KRAS alleles per 
mutant tumor cell, at least 5.5% of the cells in a 
sample has to carry the mutant allele to allow de- 
tection with PCR/ASO, while 0.02% is needed us- 
ing MEPCWASO. Our comparison of the conven- 
tional and mutant-enriched PCR based methods 
indicates that the low incidence of KRAS 12 muta- 
tions in T G C T s  must be due to the absence of 
mutations in the samples studied, and not to the 
threshold of the PCWASO. 
T h e  study of flow-sorted SE nuclei by hlulder et 
al. (1989) showed NRAS mutations in four out of 14 
cases. Three of these mutant tumors were studied 
for heterogeneity for the presence of mutant alleles 
R A S  MUTATIONS IN PRIMARY TGCTS I I S  
between separate areas within one tumor. Two  tu- 
mors were shown to be heterogeneous. Of the two 
KRAS mutant tumors, coded HT31  and HT85 in 
the study of Mulder et al. (1989), HT31 was also 
found to be heterogeneous. We confirmed the data 
on these KRAS mutant SE, which were analyzed in 
addition to the 40 SE in our series, using MEPCW 
AS0 (Fig. 2, only shown for HT85). Therefore, it 
cannot be excluded that tumor heterogeneity for 
RAS mutations leads to underestimation of the in- 
cidence of these mutations. 
A pathogenetic event can be considered of im- 
portance for tumor formation when it can be dem- 
onstrated in a high percentage of malignant cells 
within one tumor and in most independent tumors 
of the same histology. Taking together the results 
described here and those of Mulder et al. (1989), 
Moul et al. (1992), and Ridanpaa et al. (1993), a 
total incidence of RAS mutations in primary 
T G C T s  of 11% is found, with 18% in SE and 4% 
in NS. Together with the heterogeneity for RAS 
mutations withiin a single tumor (Mulder et al., 
1989), and the detection of a RAS mutation in pa- 
renchyma containing CIS and not in the adjacent 
T G C T s  (Moul et al., 1992), this supports the con- 
tention that RAS mutations are not essential in the 
initiation or progression of TGCTs .  However, a 
role of KRAS in  the development of T G C T s  by 
relative overrepresentation of (parts of) the short 
arm of chromosome 12 cannot be excluded. T h e  
difference between SE and NS concerning the in- 
cidence of mutations needs further investigation. 
T h e  question whether mutations can already be 
present in noninvasive CIS, or only in the (mi- 
cro-)invasive tumor, can be answered using micro- 
dissection of tissue sections of parenchyma under 
histological conitrol to isolate CIS cells specifically. 
Recently, Arends et al. (1993) reported on the 
suppression of apoptosis in rat fibroblast cell lines 
by mutant HRAIS. In  this context, it is interesting 
that in vitro cullture analysis revealed a consistent 
difference between 14 SE without and three with a 
RAS mutation (Olie et al., in press). Using a co- 
culture system1 with an embryonal fibroblast 
feeder, tumors ’FL1049, TL3544, and TL7573 (all 
associated with a strong hybridization signal in 
PCNASO) showed enhanced survival and prolifer- 
ation. TL8837 and TLZ191 were not available for 
in vitro culture. Frisch and Francis (1994) recently 
reported on the. induction, and abrogation by mu- 
tant HRAS, of apoptosis by disruption of epithelial 
cell-matrix interactions. Since we have indications 
that SE cells also enter apoptosis immediately after 
isolation from their micro-environment (Olie et al., 
in preparation), suppression of apoptosis by mutant 
RAS could explain the enhanced survival and pro- 
liferation in vitro of the mutant tumors. I t  is un- 
likely that dysfunction of other genes in the RAS 
pathway, mimicking the effect of RAS mutations, 
are involved in the development of T G C T s ,  be- 
cause of the absence of SE without RAS mutations 
which could be cultured in vitro. T h e  possible tu- 
mor heterogeneity of the KRAS mutation in 
TL614, suggested by the presence of less than 
5.5% mutant cells, and its relation to in vitro be- 
havior will be studied. 
N- and KRAS mutations indicate an unfavorable 
prognosis in childhood acute lymphocytic leukemia 
(Lubbert et al., 1990) and nonsmall cell lung can- 
cer, especially adenocarcinonia (Slebos et al., 1990; 
Mitsudomi et al., 1991), respectively. In addition, 
an enhanced in vitro proliferative capacity is re- 
ported for adult acute myeloid leukemia with a 
poor prognosis (Lowenberg et al., 1993). In view of 
these and our findings we will investigate the prog- 
nostic relevance of RAS mutations in TGCTs .  
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